Lead Product(s) : Methenamine Hippurate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Receives Final Approval from USFDA for Methenamine Hippurate Tablets USP, 1 Gram
Details : Methenamine Hippurate tablets works by releasing formaldehyde in acidic urine, which denatures bacterial proteins and DNA, it is indicated for recurring urinary tract infections.
Product Name : Hiprex-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 13, 2025
Lead Product(s) : Methenamine Hippurate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
